Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03350230 · ClinicalTrials.gov registry record
Embryonic Ploidy Status in the Oncofertility Population
A clinical trial, sponsored by Reproductive Medicine Associates of New Jersey.
- Completed
- Registry status
- 30
- Enrollment target
NCT03350230: Completed study, sponsored by Reproductive Medicine Associates of New Jersey.
NCT03350230 is a clinical trial that has completed, run by Reproductive Medicine Associates of New Jersey. The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03350230 has completed, sponsored by Reproductive Medicine Associates of New Jersey.
- COMPLETED
- Registry status
- 30 participants
- Enrollment target
Study Summary
looking at aneuploidy rates in embryos from patients who are going to or have undergone treatment for a malignancy with gonadotoxic treatment.
Primary Outcome
to evaluate the incidence of embryonic aneuploidy among oncofertility patients compared to the general infertility population
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2017-12-01 |
| Est. Completion | 2022-07-21 |
What the finished NCT03350230 record still lists
NCT03350230 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 30 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT03350230 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03350230 about?
NCT03350230 is a clinical study titled "Embryonic Ploidy Status in the Oncofertility Population". looking at aneuploidy rates in embryos from patients who are going to or have undergone treatment for a malignancy with gonadotoxic treatment.
What is the current status of trial NCT03350230?
This trial is currently completed. The enrollment target is 30 participants. The study started on 2017-12-01. Estimated completion is 2022-07-21.
Who is sponsoring clinical trial NCT03350230?
This trial is sponsored by Reproductive Medicine Associates of New Jersey, which has 51 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI